Switzerland
· Delayed Price · Currency is CHF Siegfried Holding AG Company Description
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
The company offers drug substances, including exclusive synthesis that manufactures custom APIs. It also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition.
In addition, the company offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy.
Further, it provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies.
The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
| Country | Switzerland |
| Founded | 1873 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 3,886 |
| CEO | Marcel Imwinkelried |
Contact Details
Address: Untere Bruehlstrasse 4 Zofingen, 4800 Switzerland | |
| Phone | 41 62 746 1111 |
| Website | siegfried.ch |
Stock Details
| Ticker Symbol | SFZN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0014284498 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marcel Imwinkelried | Chief Executive Officer and Chief Operating Officer Drug Products ad interim |
| Dr. Reto Suter Ph.D. | Chief Financial Officer |
| Stefan Randl | Chief Scientific Officer |
| Dr. Luca Dalla Torre | Chief Legal and Sustainability Officer |
| Peter Stierli | Head of Corporate Communications |
| Marianne Spane | Chief Business Officer of Drug Substances and Drug Products |
| Enno Schweinberger Ph.D. | Head Global Quality Management DS - Zofingen |
| Beatrice Harder | Head Regulatory Affairs - Site Zofingen |
| John Jones | Head of Operations - Malta |
| Florent Trouillet | Head Corporate Quality Systems - Global Quality Systems |